Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center

Rev Esp Enferm Dig. 2021 Oct 26. doi: 10.17235/reed.2021.8397/2021. Online ahead of print.ABSTRACTSecukinumab is a monoclonal antibody that inhibits interleukin - 17A. It is currently prescribed for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis, which are immune-mediated diseases that show significant co-heritability with IBD. Although this treatment appears to be well tolerated by patients, during the last years, several cases of new- onset IBD after secukinumab have been reported.PMID:34696593 | DOI:10.17235/reed.2021.8397/2021

Source: Revista Espanola de Enfermedades Digestivas - October 26, 2021 Category: Gastroenterology Authors: Asuncion Ojeda G ómez Luc ía Madero Velázquez Lidia Buend ía Sanchez Irene Pascual S ánchez Estefan ía Pérez Rabasco Ana Garc ía Monsalve Jos é Antonio González Ferrández Mariana Fe Garc ía Sepulcre Source Type: research